Surrozen (NASDAQ:SRZN) Cut to “Underweight” at JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Surrozen (NASDAQ:SRZN – Get Rating) from a neutral rating to an underweight rating in a research report sent to investors on Tuesday morning, The Fly reports.

SRZN has been the subject of several other research reports. Guggenheim lowered Surrozen from a buy rating to a neutral rating in a report on Friday, November 18th. Bank of America lowered shares of Surrozen from a neutral rating to an underperform rating in a research report on Wednesday, November 16th.

Surrozen Stock Performance

NASDAQ SRZN opened at $0.55 on Tuesday. The company has a market capitalization of $19.32 million, a PE ratio of -0.40 and a beta of -0.19. Surrozen has a 52-week low of $0.52 and a 52-week high of $9.50. The company has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $2.45.

Surrozen (NASDAQ:SRZN – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. As a group, analysts forecast that Surrozen will post -1.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Several hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Surrozen during the 1st quarter worth about $377,000. FMR LLC purchased a new stake in shares of Surrozen in the second quarter worth about $744,000. Vanguard Group Inc. boosted its position in shares of Surrozen by 3.2% in the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company’s stock valued at $984,000 after acquiring an additional 15,299 shares during the period. Finally, Board of Trustees of The Leland Stanford Junior University grew its stake in Surrozen by 3,102.9% during the third quarter. Board of Trustees of The Leland Stanford Junior University now owns 781,960 shares of the company’s stock valued at $1,580,000 after acquiring an additional 757,546 shares in the last quarter. 65.68% of the stock is currently owned by hedge funds and other institutional investors.

About Surrozen

(Get Rating)

Surrozen, Inc, a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.